News Releases

IBBR Researchers Awarded $850K from NSF to Study How Plants Defend Against Fungal Invasion


(Rockville, MD, February 25, 2020) Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $850K from the National Science Foundation (NSF) to advance our understanding of how fungi like powdery mildew infect plants including food source crops, and how plants fight back.  The will support advances in sustainable farming by revealing the mechanisms that fungi use to infect plants.

IBBR Request for Proposals (RFP): GMP Biomanufacturing Facility Available - Rockville, Maryland


The Institute for Bioscience and Biotechnology Research (IBBR) is accepting proposals to lease a bio-manufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, proof of concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing.

Fighting Acne: A New Approach Sourced From Viruses


IBBR researchers receive funding to explore the use of viral proteins against the bacteria that cause acne

(Rockville, MD, February 4, 2020) IBBR Fellow Dr. Daniel Nelson received a Technology Assessment award from the Maryland Innovation Initiative (MII) to support development of a new, easy-to -use, topical treatment modality for acne based on his endolysin research.

IBBR Researchers Receive $1.1M from FDA and NIIMBL to Support Biomanufacturing Innovation


Yu lab developing novel analytical technologies for biopharmaceutical products in collaboration with industry partners Merck and Pfizer

(Rockville, MD, November 19, 2019) IBBR Fellow Dr. Bruce Yu recently received two awards totaling $1.1M from the FDA and NIIMBL to advance the development of analytical methods for characterizing complex drugs and vaccines.

IBBR Request for Proposals (RFP): GMP Biomanufacturing Facility Available - Rockville, Maryland, USA


(Rockville, August 19, 2019) - The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Proof of Concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research... Read More

IBBR Collaborates with Integrated BioTherapeutics to Advance a Novel Approach to Treating Infectious Disease


A single therapeutic simultaneously targets bacteria and neutralizes toxins

(Rockville, MD, August 14, 2019) IBBR Fellow Dr. Daniel Nelson (Associate Professor, UMCP Department of Veterinary Medicine) and collaborators at Integrated BioTherapeutics and George Mason University recently received a $3M Phase II STTR award from the NIH to advance their novel immunotherapeutic into non-human primates and to optimize a cell line for biomanufacturing the drug.

IBBR Researchers Awarded $1M from DTRA to Develop Portable Medical Sensors


Redox information may hold key to rapidly diagnosing disease

(Rockville, MD, July 15, 2019) IBBR researchers recently received $1M from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense) to advance their work developing wearable sensors that measure biochemical information to diagnose disease. IBBR Fellow Dr. Gregory Payne (Research Professor, IBBR) is principal investigator on the award.

IBBR Investigator to Lead $3.5M NIH-Funded Project to Study Immune Response to HIV-1


Funding will support novel vaccine design aimed at improving protective antibody responses

(Rockville, MD, April 24, 2019) Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $3.5M from the National Institutes of Health (NIH) to advance understanding of the complex process by which the immune system produces highly specialized antibodies. 

IBBR Awarded NIH Grant to Investigate T Cell Biology Toward Development of Biotherapeutics


Findings may show how immune checkpoint LAG3 can be exploited to fight disease

(Rockville, MD, January 31, 2019) A team of investigators from the Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh recently received a $3.6M National Institutes of Health award to expand the scope of their T cell research involving LAG3 -- a well-known inhibitory receptor on T cells implicated in various cancers, as well as in the chronic infections associated with malaria and HIV.

IBBR Investigator to Lead $3.9M NIH-Funded Project to Develop Next-Generation HIV-1 Immunotherapy Agents


Multi-specific anti-HIV antibodies that neutralize almost all circulating HIV-1 viruses will be optimized to target persistent infection

(Rockville, MD, November 20, 2018) IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from the body.